within Pharmacolibrary.Drugs.ATC.D;

model D01AE18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tolnaftate is a synthetic antifungal drug used primarily for the topical treatment of dermatophyte infections such as athlete's foot, jock itch, and ringworm. It is available as creams, powders, and sprays, and is still approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed pharmacokinetic (PK) studies in humans reporting absorption, distribution, metabolism, or excretion parameters were identified for tolnaftate. Tolnaftate is used almost exclusively in topical formulations. Systemic absorption is considered negligible, and no clinical PK data are available. All following values are estimated or not applicable.</p><h4>References</h4><ol><li><p>AbouSamra, MM, &amp; Salama, AH (2017). Enhancement of the topical tolnaftate delivery for the treatment of tinea pedis via provesicular gel systems. <i>Journal of liposome research</i> 27(4) 324–334. DOI:<a href=&quot;https://doi.org/10.1080/08982104.2016.1239634&quot;>10.1080/08982104.2016.1239634</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27666873/&quot;>https://pubmed.ncbi.nlm.nih.gov/27666873</a></p></li><li><p>Kezutyte, T, et al., &amp; Briedis, V (2010). Assay of tolnaftate in human skin samples after in vitro penetration studies using high performance liquid chromatography. <i>Acta poloniae pharmaceutica</i> 67(4) 327–334. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20635527/&quot;>https://pubmed.ncbi.nlm.nih.gov/20635527</a></p></li><li><p>Degreef, HJ, &amp; DeDoncker, PR (1994). Current therapy of dermatophytosis. <i>Journal of the American Academy of Dermatology</i> 31(3 Pt 2) S25–S30. DOI:<a href=&quot;https://doi.org/10.1016/s0190-9622(08)81263-7&quot;>10.1016/s0190-9622(08)81263-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8077504/&quot;>https://pubmed.ncbi.nlm.nih.gov/8077504</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D01AE18;
